Skip to content
The Policy VaultThe Policy Vault

Zykadia (ceritinib) — Medica

Non-Small Cell Lung Cancer (NSCLC) – Anaplastic Lymphoma Kinase (ALK)-Positive

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has advanced or metastatic disease
  • Patient has anaplastic lymphoma kinase (ALK)-positive disease
  • The mutation is detected by an approved test

Approval duration

1 year